

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8471367/publications.pdf>

Version: 2024-02-01

82
papers

3,015
citations

185998

28
h-index

174990

52
g-index

82
all docs

82
docs citations

82
times ranked

4570
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1835-1842.	0.8	421
2	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. <i>Lancet Oncology</i> , 2014, 15, 713-721.	5.1	157
3	IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2009, 125, 887-893.	2.3	151
4	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1319-1327.	0.5	138
5	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	0.6	122
6	Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1463-1472.	2.0	110
7	Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2006, 107, 2842-2849.	2.0	98
8	Low-Dose Computed Tomography Screening for Lung Cancer and Pleural Mesothelioma in an Asbestos-Exposed Population: Baseline Results of a Prospective, Nonrandomized Feasibility Trial. An Alpe-Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). <i>Oncologist</i> , 2007, 12, 1215-1224.	1.9	82
9	Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges. <i>Cancers</i> , 2020, 12, 17.	1.7	82
10	Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2008, 13, 14-20.	1.9	73
11	Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature. <i>Oncologist</i> , 2007, 12, 451-464.	1.9	65
12	Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach. <i>Oncologist</i> , 2009, 14, 497-510.	1.9	64
13	Future Scenarios for the Treatment of Advanced Non-Small Cell Lung Cancer: Focus on Taxane-Containing Regimens. <i>Oncologist</i> , 2010, 15, 1102-1112.	1.9	64
14	Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System. <i>Frontiers in Oncology</i> , 2014, 4, 242.	1.3	63
15	The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 37, 61-67.	2.0	53
16	Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1260-1266.	0.5	46
17	Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1011.	1.0	45
18	Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer: A PET/CT Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1764-1769.	2.8	44

#	ARTICLE	IF	CITATIONS
19	Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1035.	1.8	39
20	Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine. <i>Current Drug Targets</i> , 2015, 16, 47-59.	1.0	38
21	Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review. <i>Cancers</i> , 2021, 13, 1794.	1.7	38
22	Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression. <i>International Journal of Cancer</i> , 2008, 123, 1108-1116.	2.3	37
23	Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGMâ„¢ Platform. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28765-28782.	1.8	35
24	Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. <i>Targeted Oncology</i> , 2015, 10, 393-404.	1.7	34
25	Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, 183-196.	2.0	33
26	Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. <i>Drug Discovery Today</i> , 2014, 19, 1671-1676.	3.2	33
27	Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. <i>Pharmaceutics</i> , 2021, 13, 653.	2.0	33
28	Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients. <i>Molecular Cancer</i> , 2013, 12, 97.	7.9	31
29	Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. <i>Lung Cancer</i> , 2011, 74, 529-534.	0.9	29
30	Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Nonâ€“Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1704-1708.	0.5	29
31	Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Nonâ€“Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 665-672.	0.5	28
32	Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples. <i>BMC Cancer</i> , 2016, 16, 692.	1.1	27
33	Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 2055-2062.	0.9	27
34	Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. <i>Lung Cancer</i> , 2010, 69, S11-S17.	0.9	26
35	Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages Iâ€“III Non-Small Cell Lung Cancer. <i>Disease Markers</i> , 2015, 2015, 1-18.	0.6	26
36	Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014). <i>Journal of Thoracic Oncology</i> , 2010, 5, 1354-1360.	0.5	24

#	ARTICLE	IF	CITATIONS
37	Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as α -mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 3320-3334.	1.4	24
38	Pemetrexed for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1545-1558.	0.9	24
39	The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1969-1976.	0.9	24
40	Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1351-1358.	2.0	24
41	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2014, 10, 79-90.	1.1	23
42	DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane+platinum regimen as first-line therapy for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 224-229.	0.9	23
43	Informal Caregiving Burden in Advanced Non-small Cell Lung Cancer: The HABIT study. <i>Journal of Thoracic Oncology</i> , 2007, 2, 475-480.	0.5	22
44	Oral vinorelbine in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1585-1599.	0.9	22
45	Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. <i>Molecular Medicine</i> , 2019, 25, 15.	1.9	22
46	Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 31.	0.7	21
47	Afatinib for the treatment of advanced non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 889-903.	0.9	21
48	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 573-585.	1.0	21
49	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 367-383.	1.0	21
50	Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatinib plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatinib. <i>LUX-Lung 5 (LL5)</i> . <i>Journal of Clinical Oncology</i> , 2014, 32, 8019-8019.	0.8	21
51	Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy. <i>Lung Cancer</i> , 2013, 81, 236-240.	0.9	20
52	Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 939-948.	1.4	19
53	A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. <i>Lung Cancer</i> , 2012, 76, 465-471.	0.9	19
54	Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 221-230.	2.0	17

#	ARTICLE	IF	CITATIONS
55	Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 16-26.	2.0	17
56	Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers. <i>International Journal of Epidemiology</i> , 2018, 47, 1981-1991.	0.9	16
57	Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 7720-7727.	1.4	13
58	Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy. <i>Lung Cancer</i> , 2018, 117, 64-69.	0.9	13
59	Belagenpumatucel-L for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1371-1379.	1.4	12
60	Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). <i>Lung Cancer</i> , 2004, 46, 99-106.	0.9	11
61	Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, e50-e52.	0.5	11
62	Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1007-1017.	1.4	10
63	The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1407-1412.	1.1	9
64	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1783-1793.	1.2	8
65	Management of Italian Patients With Advanced Non-Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study. <i>Clinical Lung Cancer</i> , 2014, 15, 338-345.e1.	1.1	7
66	Hematopoietic growth factors in lung cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 135-144.	1.1	7
67	Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory to our advantage?. <i>Journal of Thoracic Disease</i> , 2017, 9, 4300-4304.	0.6	7
68	Management of Non-Small Cell Lung in Cancer Patients with Stable Disease. <i>Drugs</i> , 2012, 72, 20-27.	4.9	6
69	New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 19-33.	0.9	6
70	Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/ gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7558-7558.	0.8	6
71	Bevacizumab and non-small-cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1107-1119.	1.4	5
72	Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries. <i>Current Medical Research and Opinion</i> , 2016, 32, 1577-1584.	0.9	4

#	ARTICLE	IF	CITATIONS
73	Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. <i>Cancers</i> , 2019, 11, 441.	1.7	3
74	A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 369-375.	1.1	2
75	Valutazione economica in base allo studio NAVOTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato. <i>Pharmacoeconomics Italian Research Articles</i> , 2014, 16, 1.	0.2	2
76	Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 21, 218-230.e6.	1.1	2
77	Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVOTrial 03). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110229.	1.4	2
78	Afatinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1357-1364.	0.5	1
79	Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy". <i>International Journal of Molecular Sciences</i> , 2017, 18, 1309.	1.8	1
80	Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification. <i>Journal of Thoracic Disease</i> , 2018, 10, E779-E783.	0.6	1
81	Efficacy of motesanib diphosphate in non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1771-1780.	0.9	0
82	Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?. <i>Current Medical Research and Opinion</i> , 2014, 30, 2291-2293.	0.9	0